C-reactive protein and other markers of inflammation in hemodialysis patients

Caspian Journal of Internal Medicine

Volumn 4, Issue 1, 2012, Pages 611-616

  Heidari, Behzad ^a  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

C reactive protein; Hemodialysis; Inflammation; Statin

Indexed keywords

ADIPONECTIN; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; DYSLIPIDEMIA; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; KIDNEY FAILURE; MORBIDITY; PATIENT ASSESSMENT; PERIODONTITIS; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT;

EID: 84872786146     PISSN: 20086164     EISSN: 20086172     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 2004; 38: 405-16.
2. Rao M, Jaber BL, Balakrishnan VS. Inflammatory biomarkers and cardiovascular risk: association or cause and effect? Semin Dial 2006; 19: 129-35.
3. Nusair MB, Rajpurohit N, Alpert MA. Chronic Inflammation and Coronary Atherosclerosis in Patients with End-Stage Renal Disease. Cardiorenal Med 2012; 2:117-24.
4. Taylor SP, Taylor BT. Healthcare-associated pneumonia in hemodialysis patients: Clinical outcomes in patients treated with narrow versus broad spectrum antibiotic therapy. Respirology. 2012 Oct 16. doi: 10.1111/j.1440-1843.2012.02306.x. [Epub ahead of print]
5. Yoo HH, Martin LC, Kochi AC, et al. Could albumin level explain the higher mortality in hemodialysis patients with pulmonary hypertension? BMC Nephrol 2012; 13:80.
6. Chen HA, Wang JJ, Chou CT, et al. Predictors of longterm mortality in patients with and without systemic lupus erythematosus on maintenance dialysis: a comparative study. J Rheumatol 2011; 38: 2390-4.
7. Heidari B. The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease. Caspian J Intern Med 2012; 3: 428-35.
8. Heidari B. Undifferentiated arthritis: predictive factors of persistent arthritis and treatment decisions. Caspian J Intern Med 2010; 1: 79-88.
9. Heidari B. Knee osteoarthritis prevalence, risk factors, pathogenesis and features: Part I. Caspian J Intern Med 2011; 2: 205-12.
10. Nadeem M, Stephen L, Schubert C, Davids MR. Association between periodontitis and systemic inflammation in patients with end-stage renal disease. SADJ 2009; 64: 470-3.
11. Noack B, Genco RJ, Trevisan M, et al. Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol 2001; 72: 1221-7.
12. Pejcic A, Kesic LJ, Milasin J. C-reactive protein as a systemic marker of inflammation in periodontitis. Eur J Clin Microbiol Infect Dis 2011; 30: 407-14.
13. Brito F, Almeida S, Figueredo CM, et al. Extent and severity of chronic periodontitis in chronic kidney disease patients. J Periodontal Res 2012; 47: 426-30.
14. Folsom AR, Pankow JS, Tracy RP, et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001; 88: 112-7.
15. Liu J, Wu Y, Ding Y, et al. Evaluation of serum levels of C-reactive protein and lipid profiles in patients with chronic periodontitis and/or coronary heart disease in an ethnic Han population. Quintessence Int 2010; 41: 239-47.
16. Panichi V, Rizza GM, Paoletti S, et al. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 2008; 23: 2337-43.
17. Takahashi R, Ito Y, Takahashi H, et al. Combined Values of Serum Albumin, C-Reactive Protein and Body Mass Index at Dialysis Initiation Accurately Predicts Long-Term Mortality. Am J Nephrol 2012; 36: 136-43.
18. Stenvinkel P. Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant 2002; 17:33-8.
19. Cengiz MI, Sümer P, Cengiz S, Yavuz U. The effect of the duration of the dialysis in hemodialysis patients on dental and periodontal findings. Oral Dis 2009; 15: 336-41.
20. Akdag I, Yilmaz Y, Kahvecioglu S, et al. Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: a 5-year prospective study. Nephron Clin Pract 2008; 108: c99-c105.
21. Helal I, Zerelli L, Krid M, et al. Comparison of C-reactive protein and high-sensitivity C-reactive protein levels in patients on hemodialysis. Saudi J Kidney Dis Transpl 2012; 23: 477-83.
22. Honda H, Qureshi AR, Heimbürger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-48.
23. Lippy P, Ridker PM. Inflammation and atherothrombosis. From population blong and bench research to clinical practice. J Am College Cadiol 2006; 48: A33-46.
24. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001; 59: 407-14.
25. Menon V, Wang X, Gerald T, et al. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 2003; 42: 44-52.
26. Stenvinkel P. Inflammation in end-stage renal disease--a fire that burns within. Contrib Nephrol 2005; 149: 185-99.
27. Van der Sande FM, Kooman JP, Leunissen KM. The predictive value of C-reactive protein in end-stage renal disease: is it clinically significant? Blood Purif 2006; 24: 335-41.
28. Kir HM, Eraldemir C, Dervisoglu E, Caglayan C, Kalender B. Effects of chronic kidney disease and type of dialysis on serum levels of adiponectin, TNF-alpha and high sensitive C-reactive protein. Clin Lab 2012; 58: 495-500.
29. Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 2006; 26: 523-39.
30. Chen HY, Chiu YL, Hsu SP, et al. Elevated C-reactive protein level in hemodialysis patients with moderate/severe uremic pruritus: a potential mediator of high overall mortality. QJM 2010; 103: 837-46.
31. Krane V, Winkler K, Drechsler C, et al. Association of LDL cholesterol and inflammation with cardiovascular events and
32. Shahrokh S, Heydarian P, Ahmadi F, Saddadi F, Razeghi E. Association of inflammatory biomarkers with metabolic syndrome in hemodialysis patients. Ren Fail 2012; 34: 1109-13.
33. Kanwar M, Hashem M, Rosman H, et al. Usefulness of clinical evaluation, troponins, and C-reactive protein in predicting mortality among stable hemodialysis patients. Am J Cardiol 2006; 98: 1283-7.
34. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
35. Poon PY, Szeto CC, Kwan BC, et al. Relationship between serum levels of tumour necrosis factor-related apoptosis-inducing ligand and the survival of Chinese peritoneal dialysis patients. Nephrology (Carlton) 2012; 17: 466-71.
36. Bazeley J, Bieber B, Li Y, et al. C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 2452-61.
37. Kanaan N, Goffin E, Maisin D, Struyven J, Jadoul M. CRP measurement: does the assay matter in hemodialysis patients? Clin Nephrol 2008; 70: 503-7.
38. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344:1959-65.
39. Menon V, Wang X, Greene T, et al. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 2003; 42: 44-52.
40. Yeo ES, Hwang JY, Park JE, et al. Tumor necrosis factor (TNF-alpha) and C-reactive protein (CRP) are positively associated with the risk of chronic kidney disease in patients with type 2 diabetes. Yonsei Med J 2010; 51: 519-25.
41. Krane V, Wanner C. Statins, inflammation and kidney disease. Nat Rev Nephrol 2011; 7: 385-97.
42. Dummer CD, Thome' FS, Zingano B, Lindoso A, Veronese FV. Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease. J Nephrol 2008; 21: 900-8.
43. Goicoechea M, de Vinuesa SG, Lahera V, et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: S231-5.
44. Ikejiri A, Hirano T, Murayama S, et al. Effects of atorvastatin on triglyceride-rich lipoproteins, low-densitylipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 2004; 53: 1113-7.
45. Krane V, Winkler K, Drechsler C, et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 2008; 74: 1461-7.
46. Mason JC. The statins--therapeutic diversity in renal disease? Curr Opin Nephrol Hypertens 2005; 14: 17-24.
47. Kirmizis D, Papagianni A, Dogrammatzi F, et al. Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis. J Atheroscler Thromb 2010; 17: 1256-65.
48. Navarro JF, Mora C, Muros M, García-Idoate G. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis. Nephron Clin Pract 2003; 95: c128-35.
49. Di Renzo L, Noce A, De Angelis S, et al. Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome. Pharmacol Res 2008; 57: 93-9.
50. Tsirpanlis G, Boufidou F, Manganas S, et al. Treatment with fluvastatin rapidly modulates, via different pathways, and in dependence on the baseline level, inflammation in hemodialysis patients. Blood Purif 2004; 22: 518-24.